Our work here highlights the need to introduce Shh and Bcl2 as markers to further identify and stratify CML patients who are likely to show an inferior response on Imatinib—an approach missing in the clinics currently. Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.